Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

paxvax berna gmbh - lyophilisat und lösungsmittel

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

alk-abello a/s (8010357) - dermatophagoides-pteronyssinus-allergen; dermatophagoides-farinae-allergen - lyophilisat zum einnehmen - teil 1 - lyophilisat zum einnehmen; dermatophagoides-pteronyssinus-allergen (31454) 6 standard qualitätseinheit (allergene); dermatophagoides-farinae-allergen (31453) 6 standard qualitätseinheit (allergene)

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aj vaccines a/s (4609229) - diphtherie-toxoid; tetanus-toxoid; pertussis-toxoid - injektionssuspension in einer fertigspritze - teil 1 - injektionssuspension in einer fertigspritze; diphtherie-toxoid (31572) 2 internationale einheit; tetanus-toxoid (31573) 20 internationale einheit; pertussis-toxoid (31546) 20 mikrogramm

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombinante vesikuläre stomatitis-virus (stamm indiana) mit einem löschen des envelope-glykoprotein, ersetzt, mit dem zaire ebolavirus (stamm kikwit 1995) oberfläche glykoprotein - hämorrhagische fieber, ebola - - impfstoffe - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. die verwendung von ervebo sollte in übereinstimmung mit den offiziellen empfehlungen.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - respiratorische synzytialvirusinfektionen - impfstoffe - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. siehe abschnitte 4. 2 und 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. der einsatz dieses impfstoffs sollte in übereinstimmung mit den offiziellen empfehlungen.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. anfänge der immunität wurden eine woche nach der grundimmunisierung für rhinotracheitis, calicivirus, chlamydophila felis und panleukopenie nachgewiesen. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.